Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031
The global multiomics market is estimated to reach USD 5.70 billion by 2031 from USD 3.18 billion in 2026, at a CAGR of 12.3% during the forecast period. The global multiomics market is expected to witness significant growth through 2031, driven by the increasing adoption of integrated genomic, transcriptomic, proteomic, metabolomic, and epigenomic profiling technologies. The market expansion is supported by rising demand for comprehensive biological characterization in oncology, drug discovery, precision medicine, and translational research. Advancements in single-cell analysis, spatial omics, next-generation sequencing, mass spectrometry, and AI-enabled bioinformatics platforms are further accelerating adoption. However, high technology costs, complex data integration requirements, and the need for specialized computational expertise may limit adoption across resource-constrained research environments.
“The product segment accounted for the largest share by offering in the multiomics market in 2025.”
Based on offering, the multiomics market is segmented into products and services. In 2025, products accounted for the largest share of the market, driven by widespread adoption of sequencing platforms, analytical instruments, assay kits, reagents, consumables, and software solutions required throughout multiomics workflows. These products support sample preparation, sequencing, characterization, and data analysis activities across pharmaceutical companies, biotechnology firms, academic institutions, and research laboratories. The services segment is expected to grow at the fastest rate during the forecast period, supported by increasing outsourcing of complex multiomics profiling, bioinformatics analysis, and integrated omics interpretation to specialized service providers.
“Single-cell omics accounted for the largest share, by method, in the multiomics market in 2025.”
Based on method, the multiomics market is segmented into epigenomics, single-cell omics, spatial omics, long-read & long-range sequencing, proteomics, and other methods. Single-cell omics accounted for the largest share in 2025 due to its ability to characterize cellular heterogeneity and molecular interactions at individual cell resolution. Increasing adoption in oncology, immunology, developmental biology, and drug discovery applications continues to support its leading position. Spatial omics is expected to register the fastest growth during the forecast period, driven by increasing demand for technologies that preserve tissue architecture while enabling simultaneous molecular profiling.
“The Asia Pacific is growing at the highest CAGR in the multiomics market from 2026 to 2031.”
The multiomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is expected to register the highest CAGR, driven by increasing investments in genomics and life sciences research, expanding precision medicine initiatives, and the growing adoption of next-generation sequencing (NGS), single-cell, spatial biology, and high-resolution mass spectrometry technologies. Regional growth is further supported by rising government funding for omics research, rapid expansion of biotechnology and pharmaceutical R&D, increasing availability of advanced research infrastructure, and the growing presence of contract research organizations (CROs) and genomic service providers. Additionally, the strong presence of leading regional companies such as BGI Genomics and Novogene, along with continued investments by global multiomics technology providers, is strengthening the region's capabilities in multiomics research, biomarker discovery, and precision medicine applications, making Asia Pacific the fastest-growing market during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the multiomics market by offering, method, technology, workflow, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the multiomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the multiomics market. This report covers competitive analysis of top players and upcoming startups in the multiomics market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall multiomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“The product segment accounted for the largest share by offering in the multiomics market in 2025.”
Based on offering, the multiomics market is segmented into products and services. In 2025, products accounted for the largest share of the market, driven by widespread adoption of sequencing platforms, analytical instruments, assay kits, reagents, consumables, and software solutions required throughout multiomics workflows. These products support sample preparation, sequencing, characterization, and data analysis activities across pharmaceutical companies, biotechnology firms, academic institutions, and research laboratories. The services segment is expected to grow at the fastest rate during the forecast period, supported by increasing outsourcing of complex multiomics profiling, bioinformatics analysis, and integrated omics interpretation to specialized service providers.
“Single-cell omics accounted for the largest share, by method, in the multiomics market in 2025.”
Based on method, the multiomics market is segmented into epigenomics, single-cell omics, spatial omics, long-read & long-range sequencing, proteomics, and other methods. Single-cell omics accounted for the largest share in 2025 due to its ability to characterize cellular heterogeneity and molecular interactions at individual cell resolution. Increasing adoption in oncology, immunology, developmental biology, and drug discovery applications continues to support its leading position. Spatial omics is expected to register the fastest growth during the forecast period, driven by increasing demand for technologies that preserve tissue architecture while enabling simultaneous molecular profiling.
“The Asia Pacific is growing at the highest CAGR in the multiomics market from 2026 to 2031.”
The multiomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is expected to register the highest CAGR, driven by increasing investments in genomics and life sciences research, expanding precision medicine initiatives, and the growing adoption of next-generation sequencing (NGS), single-cell, spatial biology, and high-resolution mass spectrometry technologies. Regional growth is further supported by rising government funding for omics research, rapid expansion of biotechnology and pharmaceutical R&D, increasing availability of advanced research infrastructure, and the growing presence of contract research organizations (CROs) and genomic service providers. Additionally, the strong presence of leading regional companies such as BGI Genomics and Novogene, along with continued investments by global multiomics technology providers, is strengthening the region's capabilities in multiomics research, biomarker discovery, and precision medicine applications, making Asia Pacific the fastest-growing market during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East & Africa - 5%
- 10x Genomics, Inc.
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Oxford Nanopore Technologies plc
- Bruker
- PacBio
- Danaher Corporation
- Vizgen Corporation
- Agilent Technologies, Inc
- Biognosys AG
- Merck KGaA
- QIAGEN N.V.
- Revvity, Inc.
- Waters Corporation
- Syngene International
- Bio-Rad Laboratories, Inc
- Takara Bio Inc
- Metabolon, Inc
- BGI Genomics Co., Ltd
This research report categorizes the multiomics market by offering, method, technology, workflow, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the multiomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the multiomics market. This report covers competitive analysis of top players and upcoming startups in the multiomics market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall multiomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising adoption of multiomics in precision medicine and disease stratification, rapid adoption of single-cell and spatial multiomics, increasing accessibility of high-quality integrated omics data for research, and advances in AI, machine learning, and cloud bioinformatics for cross-omics data interpretation), restraints (complexity of multiomics data integration and standardization, and high costs associated with multiomics technologies limiting widespread adoption), opportunities (growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery, and increasing emergence of single-cell proteomics for high-resolution cellular profiling), and challenges (lack of standardization across multiomics workflows) influencing the growth of multiomics market
- Product Development/Innovation: Detailed insights on newly launched products of the multiomics market
- Market Development: Comprehensive information about lucrative markets – the report analyses the Multiomics market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiomics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as 10x Genomics, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Oxford Nanopore Technologies plc (UK), and Bruker Corporation (US), among others
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 MULTIOMICS MARKET OVERVIEW
3.2 MULTIOMICS MARKET, BY OFFERING AND REGION
3.3 MULTIOMICS MARKET: GEOGRAPHIC SNAPSHOT
3.4 MULTIOMICS MARKET, BY OFFERING
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising use of multiomics in precision medicine and disease stratification
4.2.1.2 Rapid adoption of single-cell and spatial multiomics
4.2.1.3 Increasing accessibility of high-quality, integrated omics data for research
4.2.1.4 AI, machine learning, and cloud bioinformatics improving cross-omics interpretation
4.2.2 RESTRAINTS
4.2.2.1 Complexity of multiomics data integration and standardization
4.2.2.2 High costs constrain technology adoption
4.2.3 OPPORTUNITIES
4.2.3.1 Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery
4.2.3.2 Increasing emergence of single-cell proteomics for high-resolution characterization of cellular profiles
4.2.4 CHALLENGES
4.2.4.1 Lack of standardization across multiomics workflows
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025)
5.5.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT DATA FOR HS CODE 9027
5.6.2 EXPORT DATA FOR HS CODE 9027
5.6.3 IMPORT VOLUME FOR HS CODE 9027
5.6.4 EXPORT VOLUME FOR HS CODE 9027
5.7 KEY CONFERENCES & EVENTS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT/FUNDING ACTIVITY
5.10 CASE STUDY ANALYSIS
5.10.1 ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION
5.10.2 INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH
5.10.3 MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY
5.11 IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Pharmaceutical and biotechnology companies
5.11.5.2 Hospitals and diagnostic laboratories
5.11.5.3 Academic & research institutes
5.11.5.4 CROs & CDMOs
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING
6.1.2 SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING
6.1.3 HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS
6.2 ADJACENT TECHNOLOGIES
6.2.1 MICROARRAYS AND HYBRIDIZATION-BASED PROFILING
6.2.2 DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING
6.3.2 HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS
6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
6.7.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 MULTIOMICS MARKET, BY OFFERING
8.1 INTRODUCTION
8.2 PRODUCTS
8.2.1 CONSUMABLES
8.2.1.1 Increasing experiment volumes, higher multiplexing, and recurring reagent requirements support growth
8.2.1.2 Assay kits & reagents
8.2.1.2.1 Recurring assay consumption, higher multiplexing, and improved low-input performance drive market growth
8.2.1.3 Other consumables
8.2.2 INSTRUMENTS & SOFTWARE
8.2.2.1 Integrated multiomics platforms, automated workflows, and AI-enabled data interpretation strengthen demand
8.3 SERVICES
8.3.1 RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH
9 MULTIOMICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 SEQUENCING
9.2.1 LONG-READ SEQUENCING
9.2.1.1 Nanopore sequencing
9.2.1.1.1 Real-time native-molecule analysis, scalable platforms, and integrated genomic–epigenomic readouts are accelerating nanopore sequencing adoption
9.2.1.2 SMRT Sequencing
9.2.1.2.1 High-accuracy HiFi reads and lower sequencing cost to expand SMRT-based multiomics
9.2.2 OTHER SEQUENCING TECHNOLOGIES
9.3 PROTEOMICS
9.3.1 ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH
9.4 OTHER TECHNOLOGIES
10 MULTIOMICS MARKET, BY METHOD
10.1 INTRODUCTION
10.2 SINGLE-CELL OMICS
10.2.1 IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH
10.2.2 SINGLE-CELL TRANSCRIPTOMICS
10.2.2.1 Higher sample throughput, improved cell recovery, and compatibility with fixed clinical samples are expanding single-cell transcriptomics
10.2.3 SINGLE-CELL EPIGENOMICS
10.2.3.1 Growing interest in gene regulation, chromatin state, and treatment resistance is accelerating single-cell epigenomics research
10.2.4 SINGLE-CELL PROTEOMICS
10.2.4.1 Ultrasensitive mass spectrometry and higher-throughput protein quantification expanding functional analysis at single-cell resolution
10.2.5 SINGLE-CELL GENOMICS
10.2.5.1 Improved detection of clonal variation and simultaneous genotype-phenotype analysis are driving single-cell genomics adoption
10.2.6 OTHER SINGLE-CELL OMICS
10.3 PROTEOMICS
10.3.1 MS-BASED PROTEOMICS
10.3.1.1 Data-independent acquisition and improved quantitative depth to sustain MS-based proteomics leadership
10.3.2 NGS-BASED PROTEOMICS
10.3.2.1 Sequencing readouts and ultra-high-plex panels to make NGS-based proteomics the fastest-growing proteomics method
10.3.3 PCR-BASED PROTEOMICS
10.3.3.1 Sensitive proximity-amplification assays to support targeted, low-volume protein profiling
10.3.4 OTHER PROTEOMICS METHODS
10.4 SPATIAL OMICS
10.4.1 SPATIAL TRANSCRIPTOMICS
10.4.1.1 Whole-transcriptome tissue mapping and higher resolution to sustain spatial transcriptomics leadership
10.4.2 SPATIAL PROTEOMICS
10.4.2.1 Higher-plex imaging and tissue phenotyping to accelerate spatial proteomics adoption
10.4.3 SPATIAL EPIGENOMICS
10.4.3.1 Mapping regulatory states within tissue to expand spatial epigenomics from early research applications
10.4.4 SPATIAL GENOMICS
10.4.4.1 In situ variant and copy-number mapping to support spatial genomics growth
10.4.5 OTHER SPATIAL OMICS
10.5 LONG-READ & LONG-RANGE SEQUENCING
10.5.1 IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION
10.5.2 LONG-READ SEQUENCING
10.5.2.1 Higher accuracy and throughput to ensure market leadership
10.5.3 LONG-RANGE SEQUENCING
10.5.3.1 Genome mapping and linked information to improve structural and haplotype characterization
10.5.4 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS
10.6 EPIGENOMICS
10.6.1 SEQUENCING-BASED EPIGENOMICS
10.6.1.1 DNA methylation sequencing
10.6.1.1.1 Genome-wide and targeted methylation analysis to sustain the largest sequencing-based epigenomics share
10.6.1.2 Chromatin accessibility sequencing
10.6.1.2.1 ATAC-seq adoption and regulatory element mapping to make accessibility profiling the fastest-growing epigenomics method
10.6.1.3 Histone modification profiling
10.6.1.3.1 Lower-input chromatin profiling to broaden analysis of histone-associated regulatory states
10.6.1.4 Chromatin interaction analysis
10.6.1.4.1 3D genome mapping to connect distal regulatory elements with gene activity
10.6.2 OTHER EPIGENOMICS METHODS
10.7 OTHER METHODS
11 MULTIOMICS MARKET, BY WORKFLOW
11.1 INTRODUCTION
11.2 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION
11.2.1 HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS
11.3 SAMPLE PREPARATION
11.3.1 IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES
11.4 DATA VISUALIZATION & ANALYSIS
11.4.1 AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS
12 MULTIOMICS MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 ONCOLOGY
12.2.1 GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP
12.3 DRUG DISCOVERY & DEVELOPMENT
12.3.1 DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION
12.4 IMMUNOLOGY
12.4.1 LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH
12.5 PRECISION MEDICINE
12.5.1 INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT
12.6 BIOMARKER DISCOVERY
12.6.1 CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE
12.7 CELL BIOLOGY
12.7.1 HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY
12.8 TRANSLATIONAL RESEARCH
12.8.1 IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH
12.9 NEUROLOGY
12.9.1 BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS
12.10 CLINICAL DIAGNOSTICS
12.10.1 GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION
12.11 OTHER APPLICATIONS
13 MULTIOMICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION
13.3 ACADEMIC & RESEARCH INSTITUTES
13.3.1 GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES
13.4 CROS & CDMOS
13.4.1 OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS
13.5 HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES
13.5.1 CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES
14 MULTIOMICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Regulatory acceptance, clinically integrated molecular testing, and population-scale health datasets accelerate multiomics adoption
14.2.2 CANADA
14.2.2.1 Population-scale precision health initiatives expand integration capacity
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Clinical integration of genome sequencing and strong translational research networks drive market growth
14.3.2 UK
14.3.2.1 Population-scale multimodal datasets, NHS integration, and industry-backed biomarker programs propel market growth
14.3.3 FRANCE
14.3.3.1 Standardized precision-medicine pathways and strong oncology research networks drive market
14.3.4 ITALY
14.3.4.1 Shared research infrastructure widening access beyond leading academic centers
14.3.5 SPAIN
14.3.5.1 Hospital-linked genomics programs support steady adoption of integrated profiling
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Large-scale genomic initiatives and rapid adoption of precision medicine technologies drive growth
14.4.2 JAPAN
14.4.2.1 Mature biobanks and pharmaceutical research support stable, high-value adoption
14.4.3 SOUTH KOREA
14.4.3.1 National bio-data infrastructure and digital-health capabilities accelerate multiomics use
14.4.4 INDIA
14.4.4.1 GenomeIndia and expanding translational capacity propel rapid growth in Indian multiomics market
14.4.5 AUSTRALIA
14.4.5.1 Mission-led genomics investment strengthens clinical translation and data integration
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Growing genomics infrastructure and increasing precision medicine adoption drive market growth
14.5.2 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GCC COUNTRIES
14.6.1.1 Saudi Arabia
14.6.1.1.1 Rising healthcare expenditure, expanding genomics research, and investments in precision medicine to propel market
14.6.1.2 UAE
14.6.1.2.1 Large-scale citizen sequencing moves genomics toward preventive and personalized care
14.6.1.3 Rest of GCC Countries
14.6.2 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Offering footprint
15.5.5.4 Technology footprint
15.5.5.5 Workflow footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 COMPANY VALUATION
15.7.2 FINANCIAL METRICS
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT & SERVICE LAUNCHES
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY COMPANIES
16.1.1 10X GENOMICS
16.1.1.1 Business overview
16.1.1.2 Products & services offered
16.1.1.3 Recent developments
16.1.1.3.1 Product & service launches
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 THERMO FISHER SCIENTIFIC INC.
16.1.2.1 Business overview
16.1.2.2 Products & services offered
16.1.2.3 Recent developments
16.1.2.3.1 Product & service launches
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 ILLUMINA, INC.
16.1.3.1 Business overview
16.1.3.2 Products & services offered
16.1.3.3 Recent developments
16.1.3.3.1 Product & service launches
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
16.1.4.1 Business overview
16.1.4.2 Products & services offered
16.1.4.3 Recent developments
16.1.4.3.1 Deals
16.1.4.3.2 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 BRUKER
16.1.5.1 Business overview
16.1.5.2 Products & services offered
16.1.5.3 Recent developments
16.1.5.3.1 Product & service launches
16.1.5.3.2 Deals
16.1.5.4 MnM view
16.1.5.4.1 Key strengths
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 PACBIO
16.1.6.1 Business overview
16.1.6.2 Products & services offered
16.1.6.3 Recent developments
16.1.6.3.1 Product & service launches
16.1.6.3.2 Deals
16.1.7 DANAHER CORPORATION
16.1.7.1 Business overview
16.1.7.2 Products & services offered
16.1.7.3 Recent developments
16.1.7.3.1 Product & service launches
16.1.7.3.2 Deals
16.1.8 VIZGEN, INC.
16.1.8.1 Business overview
16.1.8.2 Products & services offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.9 AGILENT TECHNOLOGIES, INC.
16.1.9.1 Business overview
16.1.9.2 Products & services offered
16.1.9.3 Recent developments
16.1.9.3.1 Product & service launches
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.10 BIOGNOSYS
16.1.10.1 Business overview
16.1.10.2 Products & services offered
16.1.10.3 Recent developments
16.1.10.3.1 Deals
16.1.11 MERCK KGAA
16.1.11.1 Business overview
16.1.11.2 Products & services offered
16.1.11.3 Recent developments
16.1.11.3.1 Expansions
16.1.12 QIAGEN N.V.
16.1.12.1 Business overview
16.1.12.2 Products & services offered
16.1.12.3 Recent developments
16.1.12.3.1 Product & service launches
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 REVVITY, INC.
16.1.13.1 Business overview
16.1.13.2 Products & services offered
16.1.13.3 Recent developments
16.1.13.3.1 Product & service launches
16.1.13.3.2 Deals
16.1.14 WATERS CORPORATION
16.1.14.1 Business overview
16.1.14.2 Products & services offered
16.1.14.3 Recent developments
16.1.14.3.1 Product & service launches
16.1.14.3.2 Deals
16.1.14.3.3 Expansions
16.1.15 BIO-RAD LABORATORIES, INC.
16.1.15.1 Business overview
16.1.15.2 Products & services offered
16.1.15.3 Recent developments
16.1.15.3.1 Product & service launches
16.1.15.3.2 Deals
16.1.16 TAKARA BIO INC.
16.1.16.1 Business overview
16.1.16.2 Products & services offered
16.1.16.3 Recent developments
16.1.16.3.1 Expansions
16.1.17 METABOLON, INC.
16.1.17.1 Business overview
16.1.17.2 Products & services offered
16.1.17.3 Recent developments
16.1.17.3.1 Product & service launches
16.2 OTHER PLAYERS
16.2.1 BGI GENOMICS CO., LTD.
16.2.2 NOVOGENE CO., LTD.
16.2.3 AZENTA, INC.
16.2.4 EVOTEC SE
16.2.5 MEDGENOME LABS LTD.
16.2.6 CD GENOMICS
16.2.7 BIOGENITY
16.2.8 SAPIENT BIOANALYTICS, LLC
16.2.9 RAYBIOTECH, INC.
16.2.10 SOURCE BIOSCIENCE LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.2 PRIMARY DATA
17.2 MARKET ESTIMATION METHODOLOGY
17.2.1 MARKET SIZE ESTIMATION
17.2.2 INSIGHTS OF PRIMARY EXPERTS
17.2.3 TOP-DOWN APPROACH
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 MULTIOMICS MARKET OVERVIEW
3.2 MULTIOMICS MARKET, BY OFFERING AND REGION
3.3 MULTIOMICS MARKET: GEOGRAPHIC SNAPSHOT
3.4 MULTIOMICS MARKET, BY OFFERING
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising use of multiomics in precision medicine and disease stratification
4.2.1.2 Rapid adoption of single-cell and spatial multiomics
4.2.1.3 Increasing accessibility of high-quality, integrated omics data for research
4.2.1.4 AI, machine learning, and cloud bioinformatics improving cross-omics interpretation
4.2.2 RESTRAINTS
4.2.2.1 Complexity of multiomics data integration and standardization
4.2.2.2 High costs constrain technology adoption
4.2.3 OPPORTUNITIES
4.2.3.1 Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery
4.2.3.2 Increasing emergence of single-cell proteomics for high-resolution characterization of cellular profiles
4.2.4 CHALLENGES
4.2.4.1 Lack of standardization across multiomics workflows
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025)
5.5.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT DATA FOR HS CODE 9027
5.6.2 EXPORT DATA FOR HS CODE 9027
5.6.3 IMPORT VOLUME FOR HS CODE 9027
5.6.4 EXPORT VOLUME FOR HS CODE 9027
5.7 KEY CONFERENCES & EVENTS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT/FUNDING ACTIVITY
5.10 CASE STUDY ANALYSIS
5.10.1 ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION
5.10.2 INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH
5.10.3 MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY
5.11 IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Pharmaceutical and biotechnology companies
5.11.5.2 Hospitals and diagnostic laboratories
5.11.5.3 Academic & research institutes
5.11.5.4 CROs & CDMOs
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY TECHNOLOGIES
6.1.1 SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING
6.1.2 SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING
6.1.3 HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS
6.2 ADJACENT TECHNOLOGIES
6.2.1 MICROARRAYS AND HYBRIDIZATION-BASED PROFILING
6.2.2 DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING
6.3.2 HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS
6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
6.7.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 MULTIOMICS MARKET, BY OFFERING
8.1 INTRODUCTION
8.2 PRODUCTS
8.2.1 CONSUMABLES
8.2.1.1 Increasing experiment volumes, higher multiplexing, and recurring reagent requirements support growth
8.2.1.2 Assay kits & reagents
8.2.1.2.1 Recurring assay consumption, higher multiplexing, and improved low-input performance drive market growth
8.2.1.3 Other consumables
8.2.2 INSTRUMENTS & SOFTWARE
8.2.2.1 Integrated multiomics platforms, automated workflows, and AI-enabled data interpretation strengthen demand
8.3 SERVICES
8.3.1 RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH
9 MULTIOMICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 SEQUENCING
9.2.1 LONG-READ SEQUENCING
9.2.1.1 Nanopore sequencing
9.2.1.1.1 Real-time native-molecule analysis, scalable platforms, and integrated genomic–epigenomic readouts are accelerating nanopore sequencing adoption
9.2.1.2 SMRT Sequencing
9.2.1.2.1 High-accuracy HiFi reads and lower sequencing cost to expand SMRT-based multiomics
9.2.2 OTHER SEQUENCING TECHNOLOGIES
9.3 PROTEOMICS
9.3.1 ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH
9.4 OTHER TECHNOLOGIES
10 MULTIOMICS MARKET, BY METHOD
10.1 INTRODUCTION
10.2 SINGLE-CELL OMICS
10.2.1 IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH
10.2.2 SINGLE-CELL TRANSCRIPTOMICS
10.2.2.1 Higher sample throughput, improved cell recovery, and compatibility with fixed clinical samples are expanding single-cell transcriptomics
10.2.3 SINGLE-CELL EPIGENOMICS
10.2.3.1 Growing interest in gene regulation, chromatin state, and treatment resistance is accelerating single-cell epigenomics research
10.2.4 SINGLE-CELL PROTEOMICS
10.2.4.1 Ultrasensitive mass spectrometry and higher-throughput protein quantification expanding functional analysis at single-cell resolution
10.2.5 SINGLE-CELL GENOMICS
10.2.5.1 Improved detection of clonal variation and simultaneous genotype-phenotype analysis are driving single-cell genomics adoption
10.2.6 OTHER SINGLE-CELL OMICS
10.3 PROTEOMICS
10.3.1 MS-BASED PROTEOMICS
10.3.1.1 Data-independent acquisition and improved quantitative depth to sustain MS-based proteomics leadership
10.3.2 NGS-BASED PROTEOMICS
10.3.2.1 Sequencing readouts and ultra-high-plex panels to make NGS-based proteomics the fastest-growing proteomics method
10.3.3 PCR-BASED PROTEOMICS
10.3.3.1 Sensitive proximity-amplification assays to support targeted, low-volume protein profiling
10.3.4 OTHER PROTEOMICS METHODS
10.4 SPATIAL OMICS
10.4.1 SPATIAL TRANSCRIPTOMICS
10.4.1.1 Whole-transcriptome tissue mapping and higher resolution to sustain spatial transcriptomics leadership
10.4.2 SPATIAL PROTEOMICS
10.4.2.1 Higher-plex imaging and tissue phenotyping to accelerate spatial proteomics adoption
10.4.3 SPATIAL EPIGENOMICS
10.4.3.1 Mapping regulatory states within tissue to expand spatial epigenomics from early research applications
10.4.4 SPATIAL GENOMICS
10.4.4.1 In situ variant and copy-number mapping to support spatial genomics growth
10.4.5 OTHER SPATIAL OMICS
10.5 LONG-READ & LONG-RANGE SEQUENCING
10.5.1 IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION
10.5.2 LONG-READ SEQUENCING
10.5.2.1 Higher accuracy and throughput to ensure market leadership
10.5.3 LONG-RANGE SEQUENCING
10.5.3.1 Genome mapping and linked information to improve structural and haplotype characterization
10.5.4 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS
10.6 EPIGENOMICS
10.6.1 SEQUENCING-BASED EPIGENOMICS
10.6.1.1 DNA methylation sequencing
10.6.1.1.1 Genome-wide and targeted methylation analysis to sustain the largest sequencing-based epigenomics share
10.6.1.2 Chromatin accessibility sequencing
10.6.1.2.1 ATAC-seq adoption and regulatory element mapping to make accessibility profiling the fastest-growing epigenomics method
10.6.1.3 Histone modification profiling
10.6.1.3.1 Lower-input chromatin profiling to broaden analysis of histone-associated regulatory states
10.6.1.4 Chromatin interaction analysis
10.6.1.4.1 3D genome mapping to connect distal regulatory elements with gene activity
10.6.2 OTHER EPIGENOMICS METHODS
10.7 OTHER METHODS
11 MULTIOMICS MARKET, BY WORKFLOW
11.1 INTRODUCTION
11.2 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION
11.2.1 HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS
11.3 SAMPLE PREPARATION
11.3.1 IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES
11.4 DATA VISUALIZATION & ANALYSIS
11.4.1 AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS
12 MULTIOMICS MARKET, BY APPLICATION
12.1 INTRODUCTION
12.2 ONCOLOGY
12.2.1 GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP
12.3 DRUG DISCOVERY & DEVELOPMENT
12.3.1 DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION
12.4 IMMUNOLOGY
12.4.1 LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH
12.5 PRECISION MEDICINE
12.5.1 INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT
12.6 BIOMARKER DISCOVERY
12.6.1 CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE
12.7 CELL BIOLOGY
12.7.1 HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY
12.8 TRANSLATIONAL RESEARCH
12.8.1 IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH
12.9 NEUROLOGY
12.9.1 BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS
12.10 CLINICAL DIAGNOSTICS
12.10.1 GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION
12.11 OTHER APPLICATIONS
13 MULTIOMICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION
13.3 ACADEMIC & RESEARCH INSTITUTES
13.3.1 GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES
13.4 CROS & CDMOS
13.4.1 OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS
13.5 HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES
13.5.1 CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES
14 MULTIOMICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Regulatory acceptance, clinically integrated molecular testing, and population-scale health datasets accelerate multiomics adoption
14.2.2 CANADA
14.2.2.1 Population-scale precision health initiatives expand integration capacity
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Clinical integration of genome sequencing and strong translational research networks drive market growth
14.3.2 UK
14.3.2.1 Population-scale multimodal datasets, NHS integration, and industry-backed biomarker programs propel market growth
14.3.3 FRANCE
14.3.3.1 Standardized precision-medicine pathways and strong oncology research networks drive market
14.3.4 ITALY
14.3.4.1 Shared research infrastructure widening access beyond leading academic centers
14.3.5 SPAIN
14.3.5.1 Hospital-linked genomics programs support steady adoption of integrated profiling
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Large-scale genomic initiatives and rapid adoption of precision medicine technologies drive growth
14.4.2 JAPAN
14.4.2.1 Mature biobanks and pharmaceutical research support stable, high-value adoption
14.4.3 SOUTH KOREA
14.4.3.1 National bio-data infrastructure and digital-health capabilities accelerate multiomics use
14.4.4 INDIA
14.4.4.1 GenomeIndia and expanding translational capacity propel rapid growth in Indian multiomics market
14.4.5 AUSTRALIA
14.4.5.1 Mission-led genomics investment strengthens clinical translation and data integration
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Growing genomics infrastructure and increasing precision medicine adoption drive market growth
14.5.2 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GCC COUNTRIES
14.6.1.1 Saudi Arabia
14.6.1.1.1 Rising healthcare expenditure, expanding genomics research, and investments in precision medicine to propel market
14.6.1.2 UAE
14.6.1.2.1 Large-scale citizen sequencing moves genomics toward preventive and personalized care
14.6.1.3 Rest of GCC Countries
14.6.2 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Offering footprint
15.5.5.4 Technology footprint
15.5.5.5 Workflow footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.7.1 COMPANY VALUATION
15.7.2 FINANCIAL METRICS
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT & SERVICE LAUNCHES
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY COMPANIES
16.1.1 10X GENOMICS
16.1.1.1 Business overview
16.1.1.2 Products & services offered
16.1.1.3 Recent developments
16.1.1.3.1 Product & service launches
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 THERMO FISHER SCIENTIFIC INC.
16.1.2.1 Business overview
16.1.2.2 Products & services offered
16.1.2.3 Recent developments
16.1.2.3.1 Product & service launches
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 ILLUMINA, INC.
16.1.3.1 Business overview
16.1.3.2 Products & services offered
16.1.3.3 Recent developments
16.1.3.3.1 Product & service launches
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
16.1.4.1 Business overview
16.1.4.2 Products & services offered
16.1.4.3 Recent developments
16.1.4.3.1 Deals
16.1.4.3.2 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 BRUKER
16.1.5.1 Business overview
16.1.5.2 Products & services offered
16.1.5.3 Recent developments
16.1.5.3.1 Product & service launches
16.1.5.3.2 Deals
16.1.5.4 MnM view
16.1.5.4.1 Key strengths
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 PACBIO
16.1.6.1 Business overview
16.1.6.2 Products & services offered
16.1.6.3 Recent developments
16.1.6.3.1 Product & service launches
16.1.6.3.2 Deals
16.1.7 DANAHER CORPORATION
16.1.7.1 Business overview
16.1.7.2 Products & services offered
16.1.7.3 Recent developments
16.1.7.3.1 Product & service launches
16.1.7.3.2 Deals
16.1.8 VIZGEN, INC.
16.1.8.1 Business overview
16.1.8.2 Products & services offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.9 AGILENT TECHNOLOGIES, INC.
16.1.9.1 Business overview
16.1.9.2 Products & services offered
16.1.9.3 Recent developments
16.1.9.3.1 Product & service launches
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.10 BIOGNOSYS
16.1.10.1 Business overview
16.1.10.2 Products & services offered
16.1.10.3 Recent developments
16.1.10.3.1 Deals
16.1.11 MERCK KGAA
16.1.11.1 Business overview
16.1.11.2 Products & services offered
16.1.11.3 Recent developments
16.1.11.3.1 Expansions
16.1.12 QIAGEN N.V.
16.1.12.1 Business overview
16.1.12.2 Products & services offered
16.1.12.3 Recent developments
16.1.12.3.1 Product & service launches
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 REVVITY, INC.
16.1.13.1 Business overview
16.1.13.2 Products & services offered
16.1.13.3 Recent developments
16.1.13.3.1 Product & service launches
16.1.13.3.2 Deals
16.1.14 WATERS CORPORATION
16.1.14.1 Business overview
16.1.14.2 Products & services offered
16.1.14.3 Recent developments
16.1.14.3.1 Product & service launches
16.1.14.3.2 Deals
16.1.14.3.3 Expansions
16.1.15 BIO-RAD LABORATORIES, INC.
16.1.15.1 Business overview
16.1.15.2 Products & services offered
16.1.15.3 Recent developments
16.1.15.3.1 Product & service launches
16.1.15.3.2 Deals
16.1.16 TAKARA BIO INC.
16.1.16.1 Business overview
16.1.16.2 Products & services offered
16.1.16.3 Recent developments
16.1.16.3.1 Expansions
16.1.17 METABOLON, INC.
16.1.17.1 Business overview
16.1.17.2 Products & services offered
16.1.17.3 Recent developments
16.1.17.3.1 Product & service launches
16.2 OTHER PLAYERS
16.2.1 BGI GENOMICS CO., LTD.
16.2.2 NOVOGENE CO., LTD.
16.2.3 AZENTA, INC.
16.2.4 EVOTEC SE
16.2.5 MEDGENOME LABS LTD.
16.2.6 CD GENOMICS
16.2.7 BIOGENITY
16.2.8 SAPIENT BIOANALYTICS, LLC
16.2.9 RAYBIOTECH, INC.
16.2.10 SOURCE BIOSCIENCE LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.2 PRIMARY DATA
17.2 MARKET ESTIMATION METHODOLOGY
17.2.1 MARKET SIZE ESTIMATION
17.2.2 INSIGHTS OF PRIMARY EXPERTS
17.2.3 TOP-DOWN APPROACH
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 MULTIOMICS MARKET: IMPACT ANALYSIS
TABLE 2 MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 MULTIOMICS MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
TABLE 5 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD)
TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2023–2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND)
TABLE 9 EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND)
TABLE 10 IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
TABLE 11 EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
TABLE 12 MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 22 MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 23 MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27 LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 31 MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 76 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 119 SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 120 SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 161 GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 190 GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 197 GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 199 SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 226 GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 240 GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 242 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 255 GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 262 GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 271 EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 272 NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 279 SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 285 GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 292 GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 299 GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303 ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 306 GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 308 NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LATIN AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 MIDDLE EAST: CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 313 GCC COUNTRIES: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 315 NORTH AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316 EUROPE: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 ASIA PACIFIC: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 318 LATIN AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 MIDDLE EAST: OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 320 GCC COUNTRIES: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321 OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 322 NORTH AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 323 EUROPE: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 324 ASIA PACIFIC: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 325 LATIN AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326 MIDDLE EAST: OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 327 GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328 MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 329 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 330 NORTH AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331 EUROPE: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 332 ASIA PACIFIC: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 333 LATIN AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 334 MIDDLE EAST: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 335 GCC COUNTRIES: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336 SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 337 NORTH AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338 EUROPE: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 339 ASIA PACIFIC: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 340 LATIN AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 341 MIDDLE EAST: SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 342 GCC COUNTRIES: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 343 DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 344 NORTH AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 345 EUROPE: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 346 ASIA PACIFIC: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 347 LATIN AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 348 MIDDLE EAST: DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 349 GCC COUNTRIES: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 350 MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 1 MULTIOMICS MARKET: IMPACT ANALYSIS
TABLE 2 MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 MULTIOMICS MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
TABLE 5 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD)
TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2023–2025 (USD)
TABLE 8 IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND)
TABLE 9 EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND)
TABLE 10 IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
TABLE 11 EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
TABLE 12 MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 22 MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 23 MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 24 NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25 EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26 ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27 LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28 MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 31 MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 76 LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 119 SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 120 SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 135 NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142 NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156 NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 161 GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 163 PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 190 GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 197 GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 199 SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 226 GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 240 GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 242 LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 255 GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 262 GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 271 EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 272 NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 279 SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 280 NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 285 GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 287 NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291 MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 292 GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 294 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 299 GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 301 NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303 ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 306 GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 308 NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LATIN AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 MIDDLE EAST: CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 313 GCC COUNTRIES: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 315 NORTH AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316 EUROPE: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 ASIA PACIFIC: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 318 LATIN AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 MIDDLE EAST: OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 320 GCC COUNTRIES: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321 OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 322 NORTH AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 323 EUROPE: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 324 ASIA PACIFIC: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 325 LATIN AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326 MIDDLE EAST: OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 327 GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328 MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 329 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 330 NORTH AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331 EUROPE: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 332 ASIA PACIFIC: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 333 LATIN AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 334 MIDDLE EAST: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 335 GCC COUNTRIES: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336 SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 337 NORTH AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338 EUROPE: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 339 ASIA PACIFIC: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 340 LATIN AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 341 MIDDLE EAST: SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 342 GCC COUNTRIES: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 343 DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 344 NORTH AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 345 EUROPE: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 346 ASIA PACIFIC: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 347 LATIN AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 348 MIDDLE EAST: DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 349 GCC COUNTRIES: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 350 MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKETS COVERED AND REGIONS CONSIDERED
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL MULTIOMICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIOMICS MARKET, 2023–2026
FIGURE 5 DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET
FIGURE 9 PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 10 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 11 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14 MULTIOMICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 15 MULTIOMICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 16 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
FIGURE 17 AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD)
FIGURE 20 MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
FIGURE 23 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
FIGURE 24 NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 28 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 MULTIOMICS MARKET: COMPANY FOOTPRINT
FIGURE 30 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 32 EV/EBITDA OF KEY VENDORS
FIGURE 33 MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 34 10X GENOMICS: COMPANY SNAPSHOT (2025)
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
FIGURE 38 BRUKER: COMPANY SNAPSHOT (2025)
FIGURE 39 PACBIO.: COMPANY SNAPSHOT (2025)
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 44 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 45 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 RESEARCH DESIGN
FIGURE 49 MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 50 MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC. (2025)
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 55 MULTIOMICS MARKET CAGR PROJECTIONS
FIGURE 56 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MARKETS COVERED AND REGIONS CONSIDERED
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL MULTIOMICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIOMICS MARKET, 2023–2026
FIGURE 5 DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET
FIGURE 9 PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 10 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 11 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14 MULTIOMICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 15 MULTIOMICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 16 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
FIGURE 17 AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD)
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD)
FIGURE 20 MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
FIGURE 23 IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
FIGURE 24 NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 28 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29 MULTIOMICS MARKET: COMPANY FOOTPRINT
FIGURE 30 MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 32 EV/EBITDA OF KEY VENDORS
FIGURE 33 MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 34 10X GENOMICS: COMPANY SNAPSHOT (2025)
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
FIGURE 38 BRUKER: COMPANY SNAPSHOT (2025)
FIGURE 39 PACBIO.: COMPANY SNAPSHOT (2025)
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 44 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 45 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 RESEARCH DESIGN
FIGURE 49 MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 50 MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC. (2025)
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 55 MULTIOMICS MARKET CAGR PROJECTIONS
FIGURE 56 DATA TRIANGULATION METHODOLOGY
